ERZOFRI

Growth

paliperidone palmitate

NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

[see ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone in the listed indications is unclear. However, the drug's effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2) and serotonin Type 2 (5HT 2A )…

Indications (1)

Clinical Trials (5)

NCT04940039Phase 4Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Started Jul 2021
93 enrolled
Schizophrenia
NCT04072575Phase 3Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Started Sep 2019
178 enrolled
Schizophrenia
NCT03809325N/ACompleted

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Started Nov 2018
225 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03666715N/ACompleted

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

Started Aug 2018
55 enrolled
Schizophrenia

Loss of Exclusivity

LOE Date
Sep 24, 2039
165 months away
Patent Expiry
Sep 24, 2039

Patent Records (2)

Patent #ExpiryTypeUse Code
12128049
Oct 26, 2038
U-3968
11666573
Sep 24, 2039
U-3968